{"id":20325,"date":"2022-06-09T08:09:44","date_gmt":"2022-06-09T07:09:44","guid":{"rendered":"https:\/\/k2info.w.uib.no\/?p=20325"},"modified":"2022-06-24T12:41:39","modified_gmt":"2022-06-24T11:41:39","slug":"nye-forskernettverk-medisinsk-og-helsefaglig-forskning-3","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/nb_no\/2022\/06\/09\/nye-forskernettverk-medisinsk-og-helsefaglig-forskning-3\/","title":{"rendered":"[:no]Nye forskernettverk – medisinsk og helsefaglig forskning[:en]New research networks – medical and health research[:]"},"content":{"rendered":"

[:no]COST er en europeisk nettverksorganisasjon der de fleste landene i Europa (herunder Norge og alle EU-landene) er medlemmer. En viktig oppgave for COST er \u00e5 fremme europeisk forskningssamarbeid ved \u00e5 igangsette vitenskapelige nettverk (COST Actions). N\u00e6rmere informasjon om COST kan finnes p\u00e5 deres nettside<\/a>.<\/p>\n

I mai 2022 ble det vedtatt \u00e5 igangsette 70 nye COST-nettverk. Nettverk innenfor eller relevante for medisinsk og helsefaglig forskning er f\u00f8rt opp i listen nederst i denne e-posten<\/u>.<\/p>\n

<\/p>\n

I tillegg gir vedlagte fil en oversikt over alle<\/em> de nye COST-nettverkene, inkludert et sammendrag av det enkelte nettverk. 23. juni vil COST publisere detaljerte beskrivelser (MoU\/Memorandum of Understanding) av nettverkene. Disse vil kunne finnes via denne siden: Browse COST Actions – List of COST Actions past and ongoing | COST<\/a><\/p>\n

Norges forsknings\u00adr\u00e5d koordinerer prosessen med henblikk p\u00e5 norsk deltakelse i COST-nettverk. Vedlagt f\u00f8lger s\u00f8knadsskjema (norsk og engelsk versjon) som skal brukes av dem som \u00f8nsker \u00e5 delta i nettverkenes styringskomiteer (Management Committee\/MC). Vi ser gjerne at s\u00f8knad sendes inn s\u00e5 snart som mulig, da nettverkene vil starte opp rett over sommeren\/tidlig p\u00e5 h\u00f8sten. S\u00f8knadsskjema og CV sendes som vedlegg til e-post til Trude Dypvik: tdy@forskningsradet.no<\/a><\/p>\n

Vedlegg:
\n1) New COST Actions – booklet<\/a>
\n2) S\u00f8knadsskjema (Norsk)<\/a>
\n3) Application form (engelsk)<\/a><\/p>\n

Vennlig hilsen
\nHans Hellebostad<\/p>\n

 <\/p>\n

Nye COST-nettverk innenfor\/relevante for medisinsk og helsefaglig forskning:<\/strong><\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n
    \n
  • CA21130 \u2013 P2X receptors as a therapeutic opportunity<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21139 \u2013 3Rs concepts to improve the quality of biomedical science<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21153 \u2013 Network for implementing multiomics approaches in atherosclerotic cardiovascular disease prevention and research<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21165 \u2013 Personalized medicine in chronic kidney disease: improved outcome based on Big Data<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21168 \u2013 Improving outcome of Juvenile Inflammatory Rheumatism via universally applicable clinical practice<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21108 \u2013 European Network for Skin Engineering and Modeling<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21110 \u2013 Building an open European Network on OsteoArthritis research<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21117 \u2013 The role of IMMUnity in tackling PARKinson\u2019s disease through a Translational NETwork<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21147 \u2013 European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21122 \u2013 PROmoting GeRiAtric Medicine IN countries where it is still eMerGing<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21137 \u2013 Ethics in Dementia<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21113 \u2013 Genome Editing to Treat Human Diseases<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21115 \u2013 Iron-sulphur (FeS) clusters: from chemistry to immunology<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21151 \u2013 Generation of Human Induced Pluripotent Stem Cells from Haplo-Selected Cord Blood Samples<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21160 \u2013 Non-globular proteins in the era of Machine Learning<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21162 \u2013 Establishing a Pan-European Network on Computational Redesign of Enzymes<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21169 \u2013 Information, Coding and Biological Function: the Dynamics of Life<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21116 \u2013 Identification of biological markers for prevention and translational medicine in pancreatic cancer<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21135 \u2013 Modelling immunotherapy response and toxicity in cancer<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21140 \u2013 INTercEption of oRal CancEr develoPmenT<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21154 \u2013 Translational control in Cancer European Network<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21123 \u2013 Cancer – Understanding Prevention in Intellectual Disabilities<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21152 \u2013 Implementation Network Europe for Cancer Survivorship Care<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21105 \u2013 Blastocystis under One Health<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21111 \u2013 One Health drugs against parasitic vector borne diseases in Europe and beyond<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21132 \u2013 European Swine Influenza Network<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21145 \u2013 European Network for diagnosis and treatment of antibiotic-resistant bacterial infections<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n
    \n
  • CA21164 \u2013 TowArDs an improVement in diAgNostiCs and trEatment strategies for TB control<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n